Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?

Document Details

Document Type
Pub Defense Publication
Publication Date
Feb 01, 2022
Source ID
10.1016/j.eururo.2021.10.028

Entities

People

  • Elena V. Demidova
  • Pooja Ghatalia
  • Sanjeevani Arora

Organizations

  • AstraZeneca
  • Bristol-Myers Squibb
  • Kazan Federal University
  • Merck & Co.
  • National Cancer Institute
  • United States Department of Defense